{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:14:57Z","timestamp":1788268497999,"version":"build-2803163510"},"reference-count":23,"publisher":"American Veterinary Medical Association (AVMA)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"sc_a1\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate whether adjunctive toceranib phosphate improves survival time in dogs with nasal tumors treated with megavoltage radiation therapy using a simplified 2-tier, CT-based staging system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of 279 client-owned dogs with nasal tumors that underwent CT and megavoltage radiation therapy from 2015 through 2024 were retrospectively reviewed. Dogs were classified as stage I (no cribriform plate destruction) or stage II (cribriform plate destruction present). Survival time was analyzed using Kaplan-Meier methods and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median survival time was longer in stage I than in stage II (468 vs 191 days). Toceranib phosphate was administered to 44 dogs. In the overall cohort, dogs treated with toceranib phosphate had longer survival times than untreated dogs (389 vs 250 days). Stage-specific analysis revealed no survival benefit in stage I. In contrast, toceranib phosphate was associated with prolonged survival in stage II. Multivariable analysis confirmed that toceranib phosphate was associated with improved survival in the overall cohort and in stage II but not in stage I.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a4\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjunctive toceranib phosphate was associated with improved survival in dogs with nasal tumors with cribriform plate destruction, whereas no benefit was observed in dogs without cribriform plate destruction. These findings indicate that the therapeutic effect of toceranib phosphate is stage dependent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a5\">\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>A stage-based treatment approach may be appropriate in canine nasal tumors, with radiation therapy alone for stage I disease and combination therapy with toceranib phosphate for stage II disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/ajvr.26.03.0135","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:57:28Z","timestamp":1781204248000},"source":"Crossref","is-referenced-by-count":0,"title":["Survival outcomes in canine nasal tumors treated with megavoltage radiation therapy with or without toceranib phosphate: a retrospective study of 279 cases"],"prefix":"10.2460","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2079-4034","authenticated-orcid":true,"given":"Rui","family":"Mizuno","sequence":"first","affiliation":[{"name":"Joint Graduate School of Veterinary Science, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mori","sequence":"additional","affiliation":[{"name":"Joint Graduate School of Veterinary Science, Gifu University, Gifu, Japan"},{"name":"Animal Medical Center, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"3","key":"B1","series-title":"Vet Radiol Ultrasound","first-page":"312","article-title":"Factors influencing survival after radiotherapy of nasal tumors in 130 dogs","volume":"40","author":"LaDue TA","year":"1999","unstructured":"LaDue TA, Dodge R, Page RL, Price GS, Hauck ML, Thrall DE. Factors influencing survival after radiotherapy of nasal tumors in 130 dogs. Vet Radiol Ultrasound. 1999;40(3):312\u2013317. doi:10.1111\/j.1740-8261.1999.tb00367.x"},{"issue":"3","key":"B2","series-title":"J Am Anim Hosp Assoc","first-page":"116","article-title":"Palliation of clinical signs in 48 dogs with nasal carcinomas treated with coarse-fraction radiation therapy","volume":"44","author":"Gieger T","year":"2008","unstructured":"Gieger T, Rassnick K, Siegel S, et al. Palliation of clinical signs in 48 dogs with nasal carcinomas treated with coarse-fraction radiation therapy. J Am Anim Hosp Assoc. 2008;44(3):116\u2013123. doi:10.5326\/0440116"},{"issue":"1","key":"B3","series-title":"Vet Comp Oncol","first-page":"E68","article-title":"Linac-based stereotactic radiation therapy for canine non-lymphomatous nasal tumours: 29 cases (2013\u20132016)","volume":"16","author":"Gieger TL","year":"2018","unstructured":"Gieger TL, Nolan MW. Linac-based stereotactic radiation therapy for canine non-lymphomatous nasal tumours: 29 cases (2013\u20132016). Vet Comp Oncol. 2018;16(1):E68\u2013E75. doi:10.1111\/vco.12334"},{"issue":"6","key":"B4","series-title":"J Vet Intern Med","first-page":"2356","article-title":"A retrospective study of sinonasal tumors in 182 dogs treated with stereotactic radiotherapy (3 \u00d7 10 Gy) (2010\u20132015)","volume":"37","author":"Yoshikawa H","year":"2023","unstructured":"Yoshikawa H, Lafferty MH, Griffin LR, LaRue SM. A retrospective study of sinonasal tumors in 182 dogs treated with stereotactic radiotherapy (3 \u00d7 10 Gy) (2010\u20132015). J Vet Intern Med. 2023;37(6):2356\u20132367. doi:10.1111\/jvim.16838"},{"issue":"6","key":"B5","series-title":"Vet Radiol Ultrasound","first-page":"679","article-title":"3D conformal radiation therapy for palliative treatment of canine nasal tumors","volume":"50","author":"Buchholz J","year":"2009","unstructured":"Buchholz J, Hagen R, Leo C, et al. 3D conformal radiation therapy for palliative treatment of canine nasal tumors. Vet Radiol Ultrasound. 2009;50(6):679\u2013683. doi:10.1111\/j.1740-8261.2009.01603.x"},{"issue":"6","key":"B6","series-title":"Vet Radiol Ultrasound","first-page":"e70097","article-title":"A single-institution retrospective comparison of two radiotherapy protocols for the palliative treatment of canine nasal carcinoma","volume":"66","author":"Hayes A","year":"2025","unstructured":"Hayes A, Wong H, Preston A, Dobson J. A single-institution retrospective comparison of two radiotherapy protocols for the palliative treatment of canine nasal carcinoma. Vet Radiol Ultrasound. 2025;66(6):e70097. doi:10.1111\/vru.70097"},{"issue":"3","key":"B7","series-title":"Vet Comp Oncol","first-page":"194","article-title":"Preliminary evidence for biologic activity of toceranib phosphate (Palladia) in solid tumours","volume":"10","author":"London C","year":"2012","unstructured":"London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia) in solid tumours. Vet Comp Oncol. 2012;10(3):194\u2013205. doi:10.1111\/j.1476-5829.2011.00275.x"},{"issue":"10","key":"B8","series-title":"J Small Anim Pract","first-page":"881","article-title":"Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015\u20132020)","volume":"62","author":"Merino-Gutierrez V","year":"2021","unstructured":"Merino-Gutierrez V, Borrego JF, Puig J, Hern\u00e1ndez A, Clemente-Vicario F. Treatment of advanced-stage canine nasal carcinomas with toceranib phosphate: 23 cases (2015\u20132020). J Small Anim Pract. 2021;62(10):881\u2013885. doi:10.1111\/jsap.13387"},{"issue":"1","key":"B9","series-title":"Vet Comp Oncol","first-page":"293","article-title":"A prospective, multi-centre, veterinary radiation therapy oncology group study reveals potential efficacy of toceranib phosphate as a primary or adjuvant agent in the treatment of canine nasal carcinoma","volume":"20","author":"Ehling TJ","year":"2022","unstructured":"Ehling TJ, Klein MK, Smith L, et al. A prospective, multi-centre, veterinary radiation therapy oncology group study reveals potential efficacy of toceranib phosphate as a primary or adjuvant agent in the treatment of canine nasal carcinoma. Vet Comp Oncol. 2022;20(1):293\u2013303. doi:10.1111\/vco.12776"},{"issue":"3","key":"B10","series-title":"J Vet Med Sci","first-page":"207","article-title":"Prognosis of canine patients with nasal tumors according to modified clinical stages based on computed tomography: a retrospective study","volume":"70","author":"Kondo Y","year":"2008","unstructured":"Kondo Y, Matsunaga S, Mochizuki M, et al. Prognosis of canine patients with nasal tumors according to modified clinical stages based on computed tomography: a retrospective study. J Vet Med Sci. 2008;70(3):207\u2013212. doi:10.1292\/jvms.70.207"},{"issue":"3","key":"B11","series-title":"Vet Radiol Ultrasound","first-page":"330","article-title":"Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors","volume":"50","author":"Adams WM","year":"2009","unstructured":"Adams WM, Kleiter MM, Thrall DE, et al. Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. Vet Radiol Ultrasound. 2009;50(3):330\u2013335. doi:10.1111\/j.1740-8261.2009.01545.x"},{"issue":"7","key":"B12","series-title":"Open Vet J","first-page":"1538","article-title":"Prognostic factors and survival following radiation therapy for canine nasal tumors: a single-institution retrospective study of 166 cases","volume":"14","author":"Mizuno R","year":"2024","unstructured":"Mizuno R, Mori T. Prognostic factors and survival following radiation therapy for canine nasal tumors: a single-institution retrospective study of 166 cases. Open Vet J. 2024;14(7):1538\u20131552. doi:10.5455\/OVJ.2024.v14.i7.3"},{"issue":"3","key":"B13","series-title":"J Am Vet Med Assoc","first-page":"401","article-title":"Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993\u20132003)","volume":"229","author":"Rassnick KM","year":"2006","unstructured":"Rassnick KM, Goldkamp CE, Erb HN, et al. Evaluation of factors associated with survival in dogs with untreated nasal carcinomas: 139 cases (1993\u20132003). J Am Vet Med Assoc. 2006;229(3):401\u2013406. doi:10.2460\/javma.229.3.401"},{"key":"B14","series-title":"Front Immunol","first-page":"3107","article-title":"Combining radiotherapy with anti-angiogenic therapy and immunotherapy: a therapeutic triad for cancer?","author":"Goedegebuure RSA","year":"2019","unstructured":"Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining radiotherapy with anti-angiogenic therapy and immunotherapy: a therapeutic triad for cancer? Front Immunol. 2019;9:3107. doi:10.3389\/fimmu.2018.03107"},{"issue":"1093","key":"B15","series-title":"Br J Radiol","first-page":"20180405","article-title":"Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy","volume":"92","author":"Kanthou C","year":"2019","unstructured":"Kanthou C, Tozer G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy. Br J Radiol. 2019;92(1093):20180405. doi:10.1259\/bjr.20180405"},{"key":"B16","series-title":"Front Vet Sci","first-page":"1388493","article-title":"Expression of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, cyclooxygenase-2, survivin, E-cadherin and Ki-67 in canine nasal carcinomas and sarcomas - a pilot study","author":"Pauly LAM","year":"2024","unstructured":"Pauly LAM, Junginger J, Oechtering GU, Hewicker-Trautwein M, R\u00f6sch S. Expression of vascular endothelial growth factor receptor-2, epidermal growth factor receptor, cyclooxygenase-2, survivin, E-cadherin and Ki-67 in canine nasal carcinomas and sarcomas - a pilot study. Front Vet Sci. 2024;11:1388493. doi:10.3389\/fvets.2024.1388493"},{"issue":"1","key":"B17","series-title":"Sci Rep","first-page":"16328","article-title":"VEGF knockdown enhances radiosensitivity of nasopharyngeal carcinoma by inhibiting autophagy through the activation of mTOR pathway","volume":"10","author":"Chen L","year":"2020","unstructured":"Chen L, Lin G, Chen K, et al. VEGF knockdown enhances radiosensitivity of nasopharyngeal carcinoma by inhibiting autophagy through the activation of mTOR pathway. Sci Rep. 2020;10(1):16328. doi:10.1038\/s41598-020-73310-x"},{"issue":"3","key":"B18","series-title":"J Am Vet Med Assoc","first-page":"355","article-title":"Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs","volume":"200","author":"Hahn KA","year":"1992","unstructured":"Hahn KA, Knapp DW, Richardson RC, Matlock CL. Clinical response of nasal adenocarcinoma to cisplatin chemotherapy in 11 dogs. J Am Vet Med Assoc. 1992;200(3):355\u2013357. doi:10.2460\/javma.1992.200.03.355"},{"issue":"6","key":"B19","series-title":"Vet Radiol Ultrasound","first-page":"474","article-title":"Slow-release cisplatin combined with radiation for the treatment of canine nasal tumors","volume":"38","author":"Lana SE","year":"1997","unstructured":"Lana SE, Dernell WS, LaRue SM, et al. Slow-release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet Radiol Ultrasound. 1997;38(6):474\u2013478. doi:10.1111\/j.1740-8261.1997.tb00875.x"},{"issue":"6","key":"B20","series-title":"Vet Radiol Ultrasound","first-page":"577","article-title":"Use of radiation and a slow-release cisplatin formulation for treatment of canine nasal tumors","volume":"45","author":"Lana SE","year":"2004","unstructured":"Lana SE, Dernell WS, Lafferty MH, Withrow SJ, LaRue SM. Use of radiation and a slow-release cisplatin formulation for treatment of canine nasal tumors. Vet Radiol Ultrasound. 2004;45(6):577\u2013581. doi:10.1111\/j.1740-8261.2004.04100.x"},{"issue":"6","key":"B21","series-title":"J Vet Intern Med","first-page":"436","article-title":"Survival in dogs with nasal adenocarcinoma: 64 cases (1981\u20131995)","volume":"12","author":"Henry CJ","year":"1998","unstructured":"Henry CJ, Brewer WG, Tyler JW, et al. Survival in dogs with nasal adenocarcinoma: 64 cases (1981\u20131995). J Vet Intern Med. 1998;12(6):436\u2013439. doi:10.1111\/j.1939-1676.1998.tb02147.x"},{"issue":"11","key":"B22","series-title":"Aust Vet J","first-page":"676","article-title":"Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam","volume":"82","author":"Langova V","year":"2004","unstructured":"Langova V, Mutsaers AJ, Phillips B, Straw R. Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J. 2004;82(11):676\u2013680. doi:10.1111\/j.1751-0813.2004.tb12151.x"},{"issue":"1","key":"B23","series-title":"Vet Comp Oncol","first-page":"42","article-title":"Canine intranasal tumours treated with alternating carboplatin and doxorubicin in conjunction with oral piroxicam: 29 cases","volume":"17","author":"Woodruff M","year":"2019","unstructured":"Woodruff M, Heading KL, Bennett PF. Canine intranasal tumours treated with alternating carboplatin and doxorubicin in conjunction with oral piroxicam: 29 cases. Vet Comp Oncol. 2019;17(1):42\u201348. doi:10.1111\/vco.12443"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/87\/9\/ajvr.26.03.0135.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/87\/9\/ajvr.26.03.0135.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/87\/9\/ajvr.26.03.0135.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:25:16Z","timestamp":1788265516000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/87\/9\/ajvr.26.03.0135.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.26.03.0135","relation":{},"ISSN":["0002-9645","1943-5681"],"issn-type":[{"value":"0002-9645","type":"print"},{"value":"1943-5681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}